← Leaderboards
Edward M Newman
City Of Hope/Beckman Research Institute
$11,109,553
Attributed
$14,883,347
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–19$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$14,883,347 · 4
By mechanism
UM1$7,257,208 · 1
U01$6,361,725 · 1
P30$811,740 · 1
R01$452,674 · 1
Top collaborators
- Heinz Josef Lenz6 shared
- Primo N Lara1 shared
Most similar at City Of Hope/Beckman Research Institute
Same institution · by research overlap
- Theodore G Krontiris$13,272,552
- Timothy W Synold$3,405,481
- Stephen J Forma$14,356,218
- John S Termini$3,406,696
- Lawrence C Sowers$14,780,180
Others in their field
Top investigators on “Pharmacology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$244,272,171
- Constance Ann Benson · University Of California, San Diego$243,271,751
- Daniel R Kuritzkes · Brigham And Women'S Hospital$211,464,839
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$173,041,343
- Garret A Fitzgerald · University Of Pennsylvania$142,571,551
- David Heimbrook · Leidos Biomedical Research, Inc.$130,037,760
Research focus
PharmacologyNeoplastic CellPharmacogenomicsMethodologyPharmaceutical PreparationsPharmacodynamicsComprehensive Cancer CenterCaliforniaAreaMolecularDrug KineticsLeadClinical TrialsInnovationBaseLaboratoriesBioinformaticsCancer CenterMalignant NeoplasmsCell Cycle RegulationCancer TherapyBiological MarkersCity Of Hope Comprehensive Cancer CenterNormal Tissue Morphology
Grant awards (25)
Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$1,582,668
UM1 · FY2019 · CA · contact PI
Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$2,015,876
UM1 · FY2018 · CA · contact PI
Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$1,045,842
UM1 · FY2016 · CA · contact PI
Phase I Molecular and Clinical Pharmacodynamic Trials ETCTN$871,140
UM1 · FY2016 · CA · contact PI
Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$841,026
UM1 · FY2015 · CA · contact PI
Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$900,656
UM1 · FY2014 · CA · contact PI
Phase I Molecular and Clincal Pharmacodynamic Trials$590,190
U01 · FY2013 · CA · contact PI
Phase I Molecular and Clincal Pharmacodynamic Trials$592,432
U01 · FY2012 · CA · contact PI
Phase I Molecular and Clincal Pharmacodynamic Trials$670,333
U01 · FY2011 · CA · contact PI
Phase I Molecular and Clincal Pharmacodynamic Trials$694,650
U01 · FY2010 · CA · contact PI
Phase I Molecular and Clincal Pharmacodynamic Trials$608,527
U01 · FY2009 · CA · contact PI
Phase I Molecular and Clincal Pharmacodynamic Trials$332,000
U01 · FY2009 · CA · contact PI
Phase I Molecular and Clincal Pharmacodynamic Trials$627,578
U01 · FY2008 · CA · contact PI
Phase I Molecular and Clinical Pharmacodynamic Trials$584,953
U01 · FY2007 · CA · contact PI
Phase I Molecular and Clinical Pharmacodynamic Trials$560,758
U01 · FY2006 · CA · contact PI
Phase I Molecular and Clinical Pharmacodynamic Trials$558,034
U01 · FY2005 · CA
Phase I Molecular and Clinical Pharmacodynamic Trials$542,270
U01 · FY2004 · CA
CORE--ANALYTICAL PHARMACOLOGY$135,290
P30 · FY2002 · CA
CORE--ANALYTICAL PHARMACOLOGY$135,290
P30 · FY2002 · CA
MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS$229,684
R01 · FY2001 · CA
CORE--ANALYTICAL PHARMACOLOGY$135,290
P30 · FY2001 · CA
MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS$222,990
R01 · FY2000 · CA
CORE--ANALYTICAL PHARMACOLOGY$135,290
P30 · FY2000 · CA
CORE--ANALYTICAL PHARMACOLOGY$135,290
P30 · FY2000 · CA
CORE--ANALYTICAL PHARMACOLOGY$135,290
P30 · FY2000 · CA